Cargando…

Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease

Favipiravir has antiviral activity against influenza, West Nile virus, and yellow fever virus and against flaviviruses. The objective of this pilot study was to compare three arms: favipiravir; hydroxychloroquine; standard care (no specific SARS-CoV-2 treatment) only, in symptomatic patients infecte...

Descripción completa

Detalles Bibliográficos
Autores principales:	AlQahtani, Manaf, Kumar, Nitya, Aljawder, Dhuha, Abdulrahman, Abdulkarim, Mohamed, Mohammed Wael, Alnashaba, Fatema, Fayyad, Mohammed Abu, Alshaikh, Faisal, Alsahaf, Fatima, Saeed, Sawsan, Almahroos, Amal, Abdulrahim, Zainab, Otoom, Sameer, Atkin, Stephen L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943168/ https://www.ncbi.nlm.nih.gov/pubmed/35322077 http://dx.doi.org/10.1038/s41598-022-08794-w

Ejemplares similares

Author Correction: Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease
por: AlQahtani, Manaf, et al.
Publicado: (2022)

Time Till Viral Clearance of Severe Acute Respiratory Syndrome Coronavirus 2 Is Similar for Asymptomatic and Non-critically Symptomatic Individuals
por: Kumar, Nitya, et al.
Publicado: (2021)

COVID-19 and sickle cell disease in Bahrain
por: AbdulRahman, Abdulkarim, et al.
Publicado: (2020)

The prevalence of asymptomatic and symptomatic COVID-19 in a cohort of quarantined subjects
por: Al-Qahtani, Manaf, et al.
Publicado: (2021)

Is sickle cell disease a risk factor for severe COVID‐19 outcomes in hospitalized patients? A multicenter national retrospective cohort study
por: Abdulrahman, Abdulkarim, et al.
Publicado: (2021)

Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease
por: AlQahtani, Manaf, et al.
Publicado: (2021)

Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
por: Guner, Rahmet, et al.
Publicado: (2021)

The Efficacy and Safety of Hydroxychloroquine in Patients with COVID-19: A Multicenter National Retrospective Cohort
por: Abdulrahman, Abdulkarim, et al.
Publicado: (2021)

Is glucose-6-phosphatase dehydrogenase deficiency associated with severe outcomes in hospitalized COVID-19 patients?
por: Kumar, Nitya, et al.
Publicado: (2021)

Azithromycin/favipiravir/hydroxychloroquine: Various toxicities: 7 case reports
Publicado: (2022)

The effect of ABO blood group and antibody class on the risk of COVID-19 infection and severity of clinical outcomes
por: Almadhi, Marwa Ali, et al.
Publicado: (2021)

Azithromycin/favipiravir/hydroxychloroquine: Hypoglycaemia and off label use: case report
Publicado: (2021)

Interaction between favipiravir and hydroxychloroquine and their combined drug assessment: in silico investigations
por: Parlak, Cemal, et al.
Publicado: (2021)

Development and Validation of a Method for Quantification of Favipiravir as COVID-19 Management in Spiked Human Plasma
por: Hailat, Mohammad, et al.
Publicado: (2021)

Quarantining arriving travelers in the era of COVID-19: balancing the risk and benefits a learning experience from Bahrain
por: Abdulrahman, Abdulkarim, et al.
Publicado: (2021)

Percutaneous screw fixation of fractured neck of femur in a teenage girl with osteogenesis imperfecta. A case report
por: Alkhateeb, Jawaher Mohammed, et al.
Publicado: (2018)

Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir
por: Alosaimi, Bandar, et al.
Publicado: (2022)

Azithromycin/favipiravir/hydroxychloroquine: Lack of efficacy and off-label use: case report
Publicado: (2021)

Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial
por: Bosaeed, Mohammad, et al.
Publicado: (2021)

COVID-19 Recovery Patterns Across Alpha (B.1.1.7) and Delta (B.1.617.2) Variants of SARS-CoV-2
por: Kumar, Nitya, et al.
Publicado: (2022)

Azithromycin/favipiravir/hydroxychloroquine: Ventricular tachycardia and off-label use: 2 case reports
Publicado: (2020)

Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study
por: Alotaibi, Musim, et al.
Publicado: (2021)

Favipiravir/hydroxychloroquine/methylprednisolone: Nephrotoxicity following an off-label use: 2 case reports
Publicado: (2021)

The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers
por: Turan, Derya Bayırlı, et al.
Publicado: (2022)

Favipiravir/hydroxychloroquine/oseltamivir: Tonic clonic seizures following off label use: case report
Publicado: (2020)

Clinical and Epidemiological Characteristics of COVID-19 in a Multi-National Cohort in the Middle East
por: Mallah, Saad I., et al.
Publicado: (2021)

The high prevalence of asymptomatic SARS-CoV-2 infection reveals the silent spread of COVID-19
por: Almadhi, Marwa Ali, et al.
Publicado: (2021)

EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA
por: Delen, Leman Acun, et al.
Publicado: (2022)

Socioeconomic differences in smoking in Jordan, Lebanon, Syria, and Palestine: A cross-sectional analysis of national surveys
por: Abdulrahim, Sawsan, et al.
Publicado: (2018)

RETRACTED ARTICLE: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial
por: Dabbous, Hany M., et al.
Publicado: (2021)

Retraction Note: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial
por: Dabbous, Hany M., et al.
Publicado: (2021)

A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial
por: Bosaeed, Mohammad, et al.
Publicado: (2020)

Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 Patients
por: Tawfik, Abdulrahman, et al.
Publicado: (2022)

Tocilizumab for treating severe COVID‐19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series
por: Surabotsophon, Manoon, et al.
Publicado: (2020)

COVID-19 viral load not associated with disease severity: findings from a retrospective cohort study
por: Abdulrahman, Abdulkarim, et al.
Publicado: (2021)

Dilemma of Blunt Abdominal Trauma in Patients with Crohn’s Disease, Can Intestinal Perforation be Missed?
por: Foula, Mohammed S., et al.
Publicado: (2023)

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity
por: Kaptein, Suzanne J. F., et al.
Publicado: (2020)

Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19
por: Bosaeed, Mohammad, et al.
Publicado: (2021)

Adjunctive rifampin therapy for native valve Staphylococcus aureus endocarditis in a neonate: A case report and literature review
por: Almatrafi, Mohammed A., et al.
Publicado: (2021)

ICU admission and favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hs5tfkbr31jdtica2fpq03b9p7